ReviewVirchows Archiv : an international journal of pathology2013
GISTogram: a graphic presentation of the growing GIST complexity.
Review in Virchows Archiv : an international journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Mutational Analysis ofVeterinary sciences · 2022Article
- Article
- Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.Clinical epigenetics · 2019Article
- Somatic pharmacogenomics of gastrointestinal stromal tumor.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?Epigenetics insights · 2019Article
- Germline c.1A>C heterozygous pathogenic variant inHereditary cancer in clinical practice · 2019Article
- Telocytes are the physiological counterpart of inflammatory fibroid polyps and PDGFRA-mutant GISTs.Journal of cellular and molecular medicine · 2018Article
- Gastrointestinal stromal tumour (GIST) presenting as a strangulated inguinal hernia with small bowel obstruction.BMJ case reports · 2017Article
- Observational
- Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature.Medicine · 2016Review
- A meta-analysis of prognostic value of KIT mutation status in gastrointestinal stromal tumors.OncoTargets and therapy · 2016Article
- Syndromic gastrointestinal stromal tumors.Hereditary cancer in clinical practice · 2016Review
- Targeting gastrointestinal stromal tumors: the role of regorafenib.OncoTargets and therapy · 2016Review
- Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis.Balkan medical journal · 2015Article
- Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.International journal of molecular sciences · 2015Review
- PDGFRA-mutant syndrome.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
- Small intestinal gastrointestinal stromal tumor in a young adult woman: a case report and review of the literature.Journal of medical case reports · 2014Review
- On the prevalence of KRAS mutations in GISTs.Virchows Archiv : an international journal of pathology · 2013Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms. Since then, accumulating evidence revealed the rather heterogeneous nature of GIST, implying possible different diagnostic and therapeutic approaches for each specific case, leading to the development of drugs alternative to imatinib. In this brief commentary, we graphically represent the historical growing of genotype and phenotype evidence on GIST since 1998 in its increasing complexity by building up a graph, which we have called "GISTogram", that visually conveys most of GIST-characterizing features and the probability for each of them, either alone or in combination, to be observed in a single GIST case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.